A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC)
who have failed a first-line chemotherapeutic regimen containing oxaliplatin and
5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational
Medicinal Products (IMPs), will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5
every four weeks until complete response or disease worsening/progressing.